Testing for HCV: The first step in preventing disease transmission and improving health outcomes for HCV-infected individuals

Antiviral Therapy

Volumn 17, Issue 7 PARTB, 2012, Pages 1397-1401

  Ward, John W ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; PEGINTERFERON; RIBAVIRIN; TELAPREVIR; VIRUS ANTIBODY;

ANTIVIRAL THERAPY; DISEASE ASSOCIATION; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE DISPARITY; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK BEHAVIOR; HIGH RISK POPULATION; HUMAN; IMMUNOASSAY; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RATE; INFECTION RISK; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MORBIDITY; MORTALITY; NUCLEIC ACID TEST; POINT OF CARE TESTING; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW; SEROLOGY; UNITED STATES; VIRUS EXAMINATION; VIRUS TRANSMISSION;

HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HEPATITIS C ANTIGENS; HUMANS; MASS SCREENING; NUCLEIC ACID AMPLIFICATION TECHNIQUES; OUTCOME ASSESSMENT (HEALTH CARE); POINT-OF-CARE SYSTEMS; RNA, VIRAL; UNITED STATES;

EID: 84871976412     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2477     Document Type: Review

References (32)

1. Williams IT, Bell BP, Kuhnert W, Alter MJ. Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006. Arch Intern Med 2011; 171:242-248.
2. Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34:809-816.
3. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132:2557-2576.
4. World Health Organization. Hepatitis C. (Updated 2002. Accessed 3 October 2012.) Available from http://www.who.int/csr/disease/hepatitis/Hepc.pdf
5. Glynn SA, Kleinman SH, Schreiber GB, et al. Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991 to 1996. JAMA 2000; 284:229-235.
6. Ellingson K, Seem D, Nowicki M, et al. Estimated risk of human immunodeficiency virus and hepatitis C virus infection among potential organ donors from 17 organ procurement organizations in the United States. Am J Transplant 2011; 11:1201-1208.
7. Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 2012; 62:118-128.
8. El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res 2007; 37 Suppl 2:S88-S94.
9. Freeman RB, Jr., Steffick DE, Guidinger MK, Farmer DG, Berg CL, Merion RM. Liver and intestine transplantation in the United States, 1997-2006. Am J Transplant 2008; 8:958-976.
10. Sanyal AJ. The Institute of Medicine report on viral hepatitis: a call to action. Hepatology 2010; 51:727-728.
11. Velázquez RF, Rodriguez M, Navascues CA, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2003; 37:520-527.
12. Yang JD, Kim WR, Coelho R, et al. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011; 9:64-70.
13. Kim WR, Terrault NA, Pedersen RA, et al. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology 2009; 137:1680-1686.
14. Rein DB, Wittenborn JS, Weinbaum CM, Sabin M, Smith BD, Lesesne SB. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis 2011; 43:66-72.
15. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156:271-278.
16. Dore GJ, Thomas DL. Management and treatment of injection drug users with hepatitis C virus (HCV) infection and HCV/human immunodeficiency virus coinfection. Semin Liver Dis 2005; 25:18-32.
17. Grebely J, deVlaming S, Duncan F, Viloen M, Conway B. Current approaches to HCV infection in current and former injection drug users. J Addict Dis 2008; 27:25-35.
18. Burt RD, Hagan H, Garfein RS, Sabin K, Weinbaum C, Thiede H. Trends in hepatitis B virus, hepatitis C virus, and human immunodeficiency virus prevalence, risk behaviors, and preventive measures among Seattle injection drug users aged 18-30 years, 1994-2004. J Urban Health 2007; 84:436-454.
19. Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 2001; 91: 42-46.
20. Lucidarme D, Bruandet A, Ilef D. Incidence and risk factors of HCV and HIV infections in a cohort of intravenous drug users in the north and east of France. Epidemiol Infect 2004; 132:699-708.
21. US Department of Health and Human Services. Combating the silent epidemic of viral hepatitis: action plan for the prevention, care, and treatment of viral hepatitis. (Accessed 10 September 2012.) Available from http://www.hhs.gov/ash/initiatives/hepatitis/index.html
22. van de Laar TJ, Matthews GV, Prins M, Danta M. Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. AIDS 2010; 24:1799-1812.
23. Centers for Disease Control and Prevention. Sexual transmission of hepatitis C virus among HIV-Infected men who have sex with men - New York City, 2005-2010. MMWR Morb Mortal Wkly Rep 2011; 60:945-950.
24. Mitchell AE, Colvin HM, Palmer Beasley R. Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology 2010; 51:729-733.
25. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144:705-714.
26. Poordad F, McCone J, Jr., Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-1206.
27. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-2416.
28. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366:216-224.
29. Lee SR, Yearwood GD, Guillon GB, et al. Evaluation of a rapid, point-of-care test device for the diagnosis of hepatitis C infection. J Clin Virol 2010; 48:15-17.
30. Centers for Disease Control and Prevention. Recommendations for the identification of chronic hepatitis C virus (HCV) among persons born during 1945-1965. MMWR Recomm Rep 2012; 61 No RR-4:1-32.
31. Rein DB, Smith BD, Wittenborn JS, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med 2012; 156:263-270.
32. Centers for Disease Control and Prevention. Transmission of hepatitis C virus through transplanted organs and tissue - Kentucky and Massachusetts, 2011. MMWR Morb Mortal Wkly Rep 2011; 60:1697-1700.